<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://repositorio.ufms.br/handle/123456789/4220">
    <title>DSpace Coleção:</title>
    <link>https://repositorio.ufms.br/handle/123456789/4220</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://repositorio.ufms.br/handle/123456789/12289" />
      </rdf:Seq>
    </items>
    <dc:date>2026-04-05T18:55:28Z</dc:date>
  </channel>
  <item rdf:about="https://repositorio.ufms.br/handle/123456789/12289">
    <title>Insulinas análogas de ação rápida para o manejo de pacientes com hiperglicemia hospitalar</title>
    <link>https://repositorio.ufms.br/handle/123456789/12289</link>
    <description>Título: Insulinas análogas de ação rápida para o manejo de pacientes com hiperglicemia hospitalar
Abstract: NATS-Humap/UFMS recommends the temporary use of rapid-acting insulin analogs&#xD;
in situations of regular human insulin shortages, considering similar efficacy and safety.&#xD;
Prioritize the safest product among those already incorporated, especially for&#xD;
pregnant women (insulin aspart) and children, with attention to the budgetary impact, given that there is no provision for&#xD;
specific reimbursement by the SUS. The recommendation, aligned with Conitec's deliberation, aims to ensure&#xD;
continuity of care, patient safety, and hospital planning in emergency scenarios,&#xD;
highlighting the importance of clinical and pharmacoeconomic monitoring to ensure rational and&#xD;
sustainable use in the hospital setting.
Tipo: Parecer Técnico</description>
    <dc:date>2025-07-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

